Die Aktie von Intellia Therapeutics $NTLA (-22.13%) halbiert sich nahezu, nachdem eine klinische Studie nach einem schwerwiegenden Zwischenfall pausiert werden muss:
Intellia Therapeutics (NASDAQ:NTLA)announced a temporary pause of patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nexiguran ziclumeran (nex-z) for ATTR-CM and ATTR-PN after an October 24, 2025 safety event.
The event involved a patient dosed on September 30, 2025 who developed Grade 4 liver transaminase elevations and increased total bilirubin, met protocol pausing criteria, was hospitalized and is receiving care. The company said it is consulting experts and engaging regulators. As of October 27, 2025, >650 ATTR-CM patients are enrolled in MAGNITUDE, 47 patients in MAGNITUDE-2, and an estimated >450 patients have been dosed with nex-z. A conference call and webcast were scheduled for 8:30 a.m. ET the same day.
